Nashville Post
Tennessee Oncology has become the state’s first health care provider to participate in a registry offering a revolutionary oral breast cancer treatment aiding patients who have difficulty swallowing.
The Nashville-based entity is one of 10 oncology centers nationwide now enrolling patients for the registry.
Specifically, Tennessee Oncology will participate in CAPTURE (compliance and preference for tamoxifen registry) with Raleigh, N.C.-based DARA BioSciences, Inc., a publicly traded specialty pharmaceutical company focused on oncology supportive care products.
The CAPTURE registry is designed to gain valuable insight into adherence to prescribed tamoxifen treatment, patient preference for a liquid formulation of tamoxifen, and prevalence of difficulties in swallowing among breast cancer patients taking tamoxifen tablets.
“We are pleased to participate in CAPTURE as this registry explores breast cancer adherence issues and patient preferences relative to long-term tamoxifen therapy,” Dr. Nancy Peacock (pictured), Tennessee Oncology medical oncologist at Saint Thomas Midtown Hospital, said in a release. “The data could potentially help physicians better understand challenges faced by their breast cancer patients and develop ways to help tamoxifen patients stay on therapy to maximize its effectiveness.”
